Want to see NVS full AI Analyst Report?
NVS Stock Chart & Stats
$151.97
$0.55(0.56%)
At close: 4:00 PM EST
$151.97
$0.55(0.56%)
Day’s Range― - ―
52-Week Range$112.34 - $170.46
Previous CloseN/A
Volume597.99K
Average Volume (3M)2.11M
Market Cap
$280.08B
Enterprise Value$329.27B
Total Cash (Recent Filing)$6.98B
Total Debt (Recent Filing)$47.00B
Price to Earnings (P/E)22.0
Beta0.30
Next Earnings
Jul 21, 2026EPS Estimate
2.17Next Dividend Ex-DateN/A
Dividend Yield2.87%
Share Statistics
EPS (TTM)7.02
Shares Outstanding2,034,819,500
10 Day Avg. Volume1,579,547
30 Day Avg. Volume2,113,148
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)5.79
Price to Sales (P/S)4.88
P/FCF Ratio15.11
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue5.87
Enterprise Value/Gross Profit7.80
Enterprise Value/Ebitda14.70
Forecast
1Y Price Target
$171.30Price Target Upside12.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)8.7
Revenue Forecast (FY)$56.67B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceIncreased cash on the balance sheet has led to a modestly higher target price for Novartis.
Product DevelopmentCosentyx is maintaining its NBRx share despite increased competition and is expected to grow further with the approval of the HS indication and IV formulation.
Trial ResultsKisqali's NATALEE trial results have received positive feedback from physicians, indicating excitement for its use among eBC patients.
Bears Say
Revenue ExpectationsThe target price implies modest upside from current levels, suggesting that revenue upside is mostly priced in.
Novartis News
NVS FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest stock price was $112.34 and its highest was $170.46 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is $280.08B.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Jul 21, 2026 which is in 8 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Apr 28, 2026. The company reported $1.99 earnings per share for the quarter, missing the consensus estimate of $2.098 by -$0.108.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Undervalued.
Does Novartis AG pay dividends?
Novartis AG pays a Annually dividend of $4.74 which represents an annual dividend yield of 2.87%. See more information on Novartis AG dividends here
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 2.17.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,034,819,500 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of $1.99 in its last earnings report, missing expectations of $2.098. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in NVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novartis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$171.30 (12.72% Upside)
$171.30 (12.72% Upside)
Blogger Sentiment
Bullish
NVS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 4.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 17.5%
Last 30 Days ▲ 17.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.94%
12-Months-Change
Fundamentals
Return on Equity
31.54%
Trailing 12-Months
Asset Growth
18.60%
Trailing 12-Months
Company Description
Novartis AG
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
NVS Stock 12 Month Forecast
Average Price Target
$171.30
▲(12.72% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.38% Mutual Funds
0.06% Other Institutional Investors
98.22% Public Companies and Individual Investors